Ignite Creation Date:
2025-12-24 @ 7:41 PM
Ignite Modification Date:
2026-01-16 @ 9:35 PM
Study NCT ID:
NCT02193503
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-09-28
First Post:
2013-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MVX-ONCO-1 in Patients With Solid Tumor
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D004864', 'term': 'Equipment and Supplies'}, {'id': 'D064987', 'term': 'Cell- and Tissue-Based Therapy'}], 'ancestors': [{'id': 'D001691', 'term': 'Biological Therapy'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 34}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2014-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-09-27', 'studyFirstSubmitDate': '2013-08-26', 'studyFirstSubmitQcDate': '2014-07-15', 'lastUpdatePostDateStruct': {'date': '2023-09-28', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2014-07-17', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2022-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with Adverse Events and/or Serious Adverse Events', 'timeFrame': '18 weeks', 'description': 'Adverse events will be followed carefully at each clinic visit by the Investigator, to determine their incidence, causality and severity.'}], 'secondaryOutcomes': [{'measure': 'Delayed type hypersensitivity reactions, Induction of a specific CD8 response', 'timeFrame': '18 weeks', 'description': 'immune monitoring'}, {'measure': 'imaging and metabolic monitoring', 'timeFrame': '18 weeks'}, {'measure': 'tumor size', 'timeFrame': '18 weeks', 'description': 'document of tumor number, sites, size of lesions'}, {'measure': 'tumor pain', 'timeFrame': '18 weeks', 'description': 'intensity, site, frequency of pain, use of analgesics'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['cancer', 'solid tumors', 'gene therapy', 'cell therapy', 'encapsulation'], 'conditions': ['Solid Tumor', 'Cancer']}, 'descriptionModule': {'briefSummary': 'The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.', 'detailedDescription': 'Endpoints:\n\nPrimary: To assess safety parameters including adverse and serious adverse events (incidence, causality, severity), local and systemic tolerance to the administered study treatment, changes in laboratory values and vital signs in patients with solid tumor; Secondary: to measure some tumor responses in using imaging technique, serological tumor markers, immune monitoring and metabolic monitoring.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male or female patients aged 18 years and older with advanced metastatic cancer in progression of various sites \\[Carcinoma of lung (either small cell or non-small cell), colon, breast, pancreas (exocrine or endocrine), stomach, oesophagus, head\\&neck, thyroid, kidney, bladder, prostate, ovary, uterus (cervix or corpus); Sarcoma of soft tissue, bone, uterus, melanoma; primary brain tumor\\] where all recognized treatment are exhausted or not feasible.\n* Life expectancy: estimate of at least 4 months.\n\nExclusion Criteria:\n\n* Have participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 4 preceding weeks.\n* Have received any chemotherapy treatment in the 4 preceding weeks.\n* Serious concomitant health condition such as organ transplant requiring immunosuppressive drugs, severe psychiatric disorders.\n* History of second cancer within the last 2 years with the exception of basal cell carcinoma of skin and localized cervical carcinoma treated with curative intent.\n* Patient with a systemic disease other than cancer, that is not controlled by usual medication.\n* Therapeutic anticoagulation with coumarine or continues iv heparin. Low-molecular weight heparin (LMWH) is permitted as long as treatment can be withheld several hours prior to subcutaneous implantation.\n* Positive HIV-1, HIV-2, HTLV-1, HTLV-2, hepatitis B surface antigen, or hepatitis C antibody.'}, 'identificationModule': {'nctId': 'NCT02193503', 'briefTitle': 'MVX-ONCO-1 in Patients With Solid Tumor', 'organization': {'class': 'INDUSTRY', 'fullName': 'Maxivax SA'}, 'officialTitle': 'An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy', 'orgStudyIdInfo': {'id': 'MVX-2011-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'treatment', 'description': 'MVX-1-loaded capsules and injection of irradiated autologous tumor cells', 'interventionNames': ['Other: Treatment']}], 'interventions': [{'name': 'Treatment', 'type': 'OTHER', 'otherNames': ['- capsules MVX-1-loaded (medical device)', '- irradiated autologous tumor cells (cell therapy)'], 'description': 'Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells', 'armGroupLabels': ['treatment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1205', 'city': 'Geneva', 'state': 'Canton of Geneva', 'country': 'Switzerland', 'facility': 'Hopitaux Universitaires de Genève - HUG', 'geoPoint': {'lat': 46.20222, 'lon': 6.14569}}], 'overallOfficials': [{'name': 'Eugenio Fernandez, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'HUG'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Maxivax SA', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}